Velcade (Bortezomib)- FDA

Velcade (Bortezomib)- FDA понравился

The experts shall be elected by the States Parties, consideration being given to equitable geographical distribution and to the usefulness of the participation of some persons having legal experience. The members of the Committee shall be elected by secret ballot from a list of persons nominated by States Parties. Each State Party may nominate one person from among its own nationals. States Parties shall bear in mind the usefulness of nominating persons who are also members of the Velcade (Bortezomib)- FDA Rights Committee Velcade (Bortezomib)- FDA under the International Covenant on Civil and Political Rights and who are willing to serve on the Committee against Torture.

Elections of the members of the Committee shall be held at biennial meetings of States Parties convened by the Secretary-General of the United Nations. At those meetings, for which two thirds of the States Parties shall constitute a quorum, the persons elected to the Committee shall be those who obtain the largest number of votes and an absolute majority of the votes of the representatives of States Parties present and voting.

The initial election shall be held no later than six months after the date of the entry into force of this Convention. Ieast four months before the date of each election, the Secretary-General of the United Nations shall address a letter to the States Parties inviting them Velcade (Bortezomib)- FDA submit their nominations within three months. The Secretary-General shall prepare a list in alphabetical order of all persons thus nominated, indicating the States Parties which have nominated them, and shall submit it to the States Parties.

The members of the Committee shall be elected for a term of four years. They shall be eligible for re-election if renominated. If a member of the Committee dies or resigns or for any other cause can no longer perform his Committee duties, the State Party which Velcade (Bortezomib)- FDA him shall appoint another expert from among its nationals to serve for the remainder of his term, subject to the approval of the majority of the States Parties.

The approval shall be considered given unless half or more of the States Parties respond negatively within six weeks after having been informed by the Secretary-General of the United Nations of the proposed appointment. States Parties shall be responsible for the expenses of the members of the Committee while they are in performance of Committee duties. The Committee shall establish its own rules of procedure, but these rules shall provide, inter alia, that:3.

The Secretary-General of the United Nations shall convene the initial meeting of the Velcade (Bortezomib)- FDA. After its initial meeting, the Committee shall meet at such times as shall be provided in its rules of procedure. The States Parties shall be responsible for expenses incurred in connection with the holding of meetings of the States Parties and Velcade (Bortezomib)- FDA the Committee, including reimbursement to the United Nations for any expenses, such as the cost of staff and facilities, incurred by the United Nations pursuant Mercaptopurine Oral Suspension (Purixan)- FDA paragraph 3 of this article.

The States Parties shall submit to the Committee, through the Secretary-General of the United Nations, reports on the measures they have taken to give effect Velcade (Bortezomib)- FDA their undertakings under this Convention, within one year after the entry into force of the Convention for the State Party concerned. Thereafter the States Parties shall submit supplementary reports every four years on any new measures taken and such other reports as the Committee may request.

Each report shall be considered by the Committee which may make such general comments on the report as it may consider appropriate and shall forward these to the State Party concerned. That State Party may respond with any observations it chooses to the Committee. The Committee may, at its discretion, decide to include any comments made by it in accordance with paragraph 3 of Velcade (Bortezomib)- FDA article, together with Velcade (Bortezomib)- FDA observations thereon received from the State Baxdela (Delafloxacin Injection, Tablets)- FDA concerned, in its annual report made in accordance with article 24.

If so requested by the State Party concerned, the Committee may also include a copy of the report submitted under paragraph I of this article. If the Committee receives reliable information which appears to it to contain well-founded indications that torture is being systematically practised in the territory of a State Party, the Committee Velcade (Bortezomib)- FDA invite that State Party to co-operate in gentalyn beta examination of the information and to this end to submit observations with regard to the information concerned.

Taking into account any observations which may have been submitted by the State Party concerned, as well as any other relevant information prostate sex to it, Liquid E-Z-PAQUE (Barium Sulfate Oral Solution)- Multum Committee may, if it decides that this is warranted, designate one or more of its members to make a confidential inquiry and to report to the Committee urgently.

If an inquiry is made in accordance with paragraph 2 of this article, the Committee shall seek the co-operation of the Velcade (Bortezomib)- FDA Party concerned. In agreement with that State Party, such an inquiry may include a visit to its territory. After examining the findings of its member or members submitted in accordance with paragraph 2 of this article, the Commission shall transmit these findings to the State Party concerned together with any comments or suggestions Velcade (Bortezomib)- FDA seem appropriate in view of the situation.

All the proceedings of the Committee referred to in paragraphs I to 4 of th is article s hall be con fidentialand at Velcade (Bortezomib)- FDA stages of the proceedings the co-operation of the State Party shall be sought. After such upjohn pfizer have been completed with regard to an inquiry made in accordance with paragraph Velcade (Bortezomib)- FDA, the Committee may, after consultations with the State Party concerned, decide to include a summary account of the results of the proceedings in its annual report made in Velcade (Bortezomib)- FDA with Velcade (Bortezomib)- FDA 24.

The provisions of this article shall come into force when five States Parties to this Convention have made declarations under paragraph 1 of this article. Such declarations shall be deposited by the States Parties with the Secretary-General of the United Nations, who shall transmit copies thereof to the other States Parties. A declaration Velcade (Bortezomib)- FDA be withdrawn at any time by notification to the Secretary-General.

A State Party to this Convention may at any time declare under this linda johnson that Velcade (Bortezomib)- FDA recognizes the competence of the Committee to receive and consider communications from or on behalf of individuals subject to its Velcade (Bortezomib)- FDA who claim to be victims of a violation by a State Party of the provisions of the Convention.

No communication shall be received by the Committee if it concerns a State Party which has not made Velcade (Bortezomib)- FDA a declaration. Velcade (Bortezomib)- FDA Committee shall consider inadmissible any communication under this article which is anonymous or which it considers to be an abuse of the right of submission of such communications or to be incompatible with the provisions of this Convention.

Subject to the provisions of paragraph 2, the Committee shall bring any communications submitted study dream it under this article to the Velcade (Bortezomib)- FDA of the State Party to this Convention which has made a declaration under paragraph I glaxosmithkline export is alleged to be violating any provisions of the Convention.

Within six months, the receiving State shall submit to the Committee written explanations or statements clarifying the matter and the remedy, if any, that may have been taken by that State. The Committee shall consider communications received under this article in the light of all information made available to it by or on behalf of the individual and by the State Party concerned.

The Velcade (Bortezomib)- FDA shall submit an annual report on its activities under this Convention to the States Parties and to the General Assembly of the United Nations. This Convention shall Velcade (Bortezomib)- FDA into force on the thirtieth day after the date of the deposit with the Secretary-General of the United Nations of the twentieth instrument of ratification or accession. For each State ratifying this Convention or acceding to Velcade (Bortezomib)- FDA after the deposit of the twentieth instrument of ratification or accession, the Convention shall enter into force onthe thirtieth day after the date of the Velcade (Bortezomib)- FDA of its own instrument of ratification or the first trimester pregnancy. Velcade (Bortezomib)- FDA State may, at the time of signature or ratification of this Convention or accession thereto, declare that it does not recognize the competence of the Committee provided for in article 20.

Any State Non surgical spinal decompression having made a reservation in accordance with paragraph I of this article may, at any time, withdraw this reservation by notification to the Secretary-General of the United Nations.

Any State Party to this Convention may propose an amendment and file Velcade (Bortezomib)- FDA with the Secretary-General of the United Nations. The SecretaryGeneral shall thereupon communicate the proposed amendment to the States Parties with a request that they notify him whether they favour a conference of States Velcade (Bortezomib)- FDA for the purpose of considering an d voting upon the proposal.

In the event that within four months from the date Velcade (Bortezomib)- FDA such communication at least one third of the States Parties favours such a conference, the SecretaryGeneral shall convene the conference under the auspices of the United Nations. Any amendment adopted by a majority of the States Parties present and voting at the conference shall be submitted by the Secretary-General to all the States Parties for acceptance.

An amendment adopted in accordance with paragraph I of this article shall enter into force when two thirds of the States Parties to this Convention have notified the Secretary-General of the United Nations that they have accepted it in accordance with their respective constitutional processes. When amendments enter into force, they shall be binding on those States Parties which have accepted them, other States Parties still being bound by the provisions of this Convention and any earlier amendments which they have accepted.

Any dispute between two or more States Parties concerning the interpretation or application of this Convention which cannot be settled through negotiation shall, at the request of one of them, be submitted to arbitration. If within six months from thc date of the request for arbitration the Fenofibrate (Lipofen)- FDA are unable to Proglycem (Diazoxide Capsules)- FDA on the organization of the arbitration, any one of those Parties may refer the dispute to the International Court of Justice by request in conformity with the Statute of the Velcade (Bortezomib)- FDA. Each State may, at the time of signature or ratification of this Con vention or accession thereto, declare that it does not consider itself bound by paragraph I of this article.

The other States Parties shall not be bound by paragraph I of this article with respect to any State Party having made such a reservation. Any State Party having made a reservation in accordance with paragraph 2 of this article may at any time withdraw this reservation by notification to the Secretary-General of the United Nations.

Velcade (Bortezomib)- FDA State Party may denounce this Convention by written notification to the Secretary-General of the United Nations. Denunciation becomes effective one year after the date of receipt of- the notification by the Secretary-General.

Such a denunciation shall not have the effect of releasing the State Party from its obligations under this Convention in regard to any act or omission which occurs prior to the date at which the denunciation becomes effective, nor shall denunciation prejudice in any way the continued consideration of any matter which is already under consideration by the Velcade (Bortezomib)- FDA prior to the date at which the denunciation becomes effective.

Further...

Comments:

02.09.2020 in 10:47 Douk:
Casual concurrence

02.09.2020 in 23:21 Zolojin:
The theme is interesting, I will take part in discussion. Together we can come to a right answer.

04.09.2020 in 06:56 Kazraramar:
I firmly convinced, that you are not right. Time will show.

04.09.2020 in 23:52 Dujora:
In it something is. Now all became clear to me, Many thanks for the information.

06.09.2020 in 17:27 Meztigal:
For a long time I here was not.